Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Amortization of Deferred Charges (2016 - 2025)

Dexcom (DXCM) has disclosed Amortization of Deferred Charges for 11 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Amortization of Deferred Charges fell 10.53% to $1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.3 million, a 2.67% decrease, with the full-year FY2025 number at $7.3 million, down 2.67% from a year prior.
  • Amortization of Deferred Charges was $1.7 million for Q4 2025 at Dexcom, down from $1.9 million in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $2.2 million in Q3 2023 to a low of $1.4 million in Q4 2021.
  • A 5-year average of $1.8 million and a median of $1.8 million in 2024 define the central range for Amortization of Deferred Charges.
  • Peak YoY movement for Amortization of Deferred Charges: fell 23.81% in 2022, then surged 46.67% in 2023.
  • Dexcom's Amortization of Deferred Charges stood at $1.4 million in 2021, then increased by 14.29% to $1.6 million in 2022, then rose by 25.0% to $2.0 million in 2023, then fell by 5.0% to $1.9 million in 2024, then fell by 10.53% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Amortization of Deferred Charges are $1.7 million (Q4 2025), $1.9 million (Q3 2025), and $1.8 million (Q2 2025).